Symposium “Prostate Cancer: Spot It in Time!”
Abstract
Prostate cancer (PC) is a leading cause of cancer morbidity and mortality among men worldwide1 . In this regard, the issues of diagnosis and treatment of this disease are of major importance for the healthcare system. Primary and specified diagnosis of PC, tools that can be useful in stratifying patients into risk levels – these and other topical issues were addressed at the symposium: Prostate Cancer: Spot It in Time.
References
1. Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340–351. https://doi.org/10.1016/j.eururo.2019.02.033.
2. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86(2):148–163. https://doi.org/10.1016/j.eururo.2024.03.027.
3. Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2018;73(1):81–91. https://doi.org/10.1016/j.eururo.2017.03.042.
4. Zhan Y, Zhang G, Li M, Zhou X. Whole-Body MRI vs. PET/CT for the Detection of Bone Metastases in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2021;11:633833. https://doi.org/10.3389/fonc.2021.633833.
5. Chang CY, Garner HW, Ahlawat S, Amini B, Bucknor MD, Flug JA et al. Society of Skeletal Radiology – white paper. Guidelines for the diagnostic management of incidental solitary bone lesions on CT and MRI in adults: bone reporting and data system (Bone-RADS). Skeletal Radiol. 2022;51(9):1743–1764. https://doi.org/10.1007/s00256-022-04022-8.
6. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386(12):1132–1142. https://doi.org/10.1056/NEJMoa2119115.
7. Panebianco V, Villeirs G, Weinreb JC, Turkbey BI, Margolis DJ, Richenberg J et al. Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus-based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. Eur Urol Oncol. 2021;4(6):868–876. https://doi.org/10.1016/j.euo.2021.01.003.
8. Guo W, Li M. Clinical efficacy of different androgen deprivation therapies for prostate cancer and evaluation based on dynamic-contrast enhanced magnetic resonance imaging. Acta Biochim Pol. 2024;71:12473. https://doi.org/10.3389/abp.2024.12473.
Review
For citations:
Symposium “Prostate Cancer: Spot It in Time!”. Meditsinskiy sovet = Medical Council. 2024;(21):17-22. (In Russ.)
Views:
114
Email this article 